Atom Therapeutics to Present Positive Data from Clinical Trials of Its Lead Novel Oral Drugs for Chronic Gout and Acute Gout Flares at ACR Convergence 2025
Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will present two abstracts detailing positive clinical trial data for the company’s two lead drugs, lingdolinurad (ABP-671) for chronic gout and ABP-745 for acute gout flares, at the American College of Rheumatology’s ACR Convergence 2025, October 24 – 29, 2025, in Chicago.
Atom Therapeutics Announces Positive Topline Results of Lingdolinurad (ABP-671) in Phase 2b/3 Trial for Chronic Gout
Atom Therapeutics Co., Ltd, a clinical stage biotechnology company developing best-in-class treatments for metabolic and inflammatory diseases, announced today its global Phase 2b/3 clinical trial of lingdolinurad (ABP-671), a novel orally administered URAT1 inhibitor, achieved its primary endpoint with significant efficacy in lowering serum uric acid (sUA) levels and demonstrated good safety and tolerability in treatment of patients with chronic gout.
